Back to Authors

Hu, Bei

https://orcid.org/0009-0008-2687-0174

A5036992616 | I4210100342

Mayo Clinic

Levine Cancer Institute

Citations 3

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1481-1484

10.1182/blood-2022-160090

Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1488-1490

10.1182/blood-2022-166887

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristin

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6623-6626

10.1182/blood-2022-157761